Evommune stock tumbles 38% after EVO756 misses Phase 2b CSU endpoint

Levi & Korsinsky said it is investigating whether statements about the lead drug candidate's clinical prospects and development status were materially misleading after the June 29 disclosure.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.